Literature DB >> 28062514

Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis.

Daniel Dumitrescu1,2, Christian Nagel3,4, Gabor Kovacs5, Tom Bollmann6, Michael Halank7, Jörg Winkler8, Martin Hellmich9, Ekkehard Grünig3, Horst Olschewski5, Ralf Ewert6, Stephan Rosenkranz1,2.   

Abstract

OBJECTIVES: Pulmonary arterial hypertension (PAH) is a devastating disease with limited survival and occurs as a frequent complication in patients with systemic sclerosis (SSc). A definite diagnosis of PAH is obtained by right heart catheterisation (RHC); however, the initial suspicion is raised by non-invasive methods. We assessed the diagnostic accuracy of key parameters derived from cardiopulmonary exercise testing (CPET) for detecting and ruling out SSc-associated PAH.
METHODS: In a multicentre setting, we prospectively evaluated 173 consecutive patients with SSc without known PAH, but with clinical suspicion of PAH. Each patient underwent CPET and RHC.
RESULTS: RHC identified PAH in 48 patients (27.8%), postcapillary pulmonary hypertension (PH) in 10 patients (5.8%) and ruled out PH in 115 patients (66.5%). CPET parameters correlated significantly with pulmonary haemodynamics. PeakVO2 and VE/VCO2 showed highest correlations with pulmonary arterial pressure, transpulmonary pressure gradient and pulmonary vascular resistance. Several parameters showed high sensitivity and specificity for PAH detection by receiver operating characteristic analysis. However, peakVO2 showed highest diagnostic accuracy (sensitivity 87.5%, specificity 74.8% at a threshold level of 13.8 mL/min/kg). A peakVO2 of >18.7 mL/kg/min was reached by 38/173 patients (22%) and excluded PAH in our cohort (negative predictive value 1.0). A nadir VE/VCO2 ratio of >45.5 showed a positive predictive value of 1.0. Diagnostic accuracy was highest in patients with low pulmonary arterial wedge pressure (<12 mm Hg). There were no study-related serious adverse events.
CONCLUSIONS: CPET is a safe and valuable method in the non-invasive detection of SSc-associated PAH. It may be particularly beneficial for reducing unnecessary RHC procedures. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Year:  2017        PMID: 28062514     DOI: 10.1136/heartjnl-2016-309981

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

Review 1.  [Pulmonary hypertension in connective tissue disease].

Authors:  E I Schwarz; S Ulrich
Journal:  Z Rheumatol       Date:  2018-04       Impact factor: 1.372

2.  Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Authors:  Amber Young; Vivek Nagaraja; Mark Basilious; Mirette Habib; Whitney Townsend; Heather Gladue; David Badesch; J Simon R Gibbs; Deepa Gopalan; Alessandra Manes; Ronald Oudiz; Toru Satoh; Adam Torbicki; Fernando Torres; Vallerie McLaughlin; Dinesh Khanna
Journal:  Semin Arthritis Rheum       Date:  2018-10-14       Impact factor: 5.532

Review 3.  [Functional diagnostics in pneumology].

Authors:  M Held; S Baron; B Jany
Journal:  Internist (Berl)       Date:  2018-01       Impact factor: 0.743

Review 4.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

5.  In systemic sclerosis TAPSE/sPAP ratio is correlated with ventilatory efficiency and exercise capacity assessed by CPET.

Authors:  Amalia Colalillo; Chiara Pellicano; Antonella Romaniello; Edoardo Rosato
Journal:  Clin Exp Med       Date:  2022-02-12       Impact factor: 3.984

Review 6.  A review of exercise pulmonary hypertension in systemic sclerosis.

Authors:  Faisal Shaikh; Zafia Anklesaria; Tasneam Shagroni; Rajeev Saggar; Luna Gargani; Eduardo Bossone; Michael Ryan; Richard Channick; Rajan Saggar
Journal:  J Scleroderma Relat Disord       Date:  2019-06-14

Review 7.  Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis.

Authors:  Gabor Kovacs; Horst Olschewski
Journal:  J Scleroderma Relat Disord       Date:  2019-05-24

8.  Correlation of Hemodynamic and Respiratory Parameters in Invasive Cardiopulmonary Exercise Testing (iCPET).

Authors:  Dirk Habedank; Anne Obst; Alexander Heine; Beate Stubbe; Ralf Ewert
Journal:  Life (Basel)       Date:  2022-04-28

Review 9.  An Update on Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: a Review of the Current Literature.

Authors:  Sneha M Sundaram; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2018-02-27       Impact factor: 4.592

10.  Cardiopulmonary exercise testing and prognosis in patients with systemic sclerosis without baseline pulmonary hypertension: a prospective cohort study.

Authors:  Vasiliki-Kalliopi Bournia; Anastasios Kallianos; Stylianos Panopoulos; Elias Gialafos; Lemonia Velentza; Panayiotis G Vlachoyiannopoulos; Petros P Sfikakis; Georgia Trakada
Journal:  Rheumatol Int       Date:  2021-06-29       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.